NMTC NEUROONE MEDICAL TECHNOLOGIES CORP

NeuroOne® to Present at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference

NeuroOne® to Present at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference

EDEN PRAIRIE, Minn., March 05, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced that it will participate in the upcoming Oppenheimer 35th Annual Healthcare Conference MedTech & Services Conference on Wednesday, March 19, 2025.

NeuroOne CEO Dave Rosa will host a virtual corporate presentation at 9:20 a.m. eastern time on Wednesday, March 19, 2025, followed by one-on-one meetings, which can be requested through Oppenheimer. To join live or view a replay of the webcast, please visit or the events page on NeuroOne’s investors relations website.

About NeuroOne

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit .

IR Contact

Chris Donovan

MZ Group – MZ North America



(914) 352-5853



EN
05/03/2025

Underlying

NMTCNEUROONE MEDICAL TECHNOLOGIES CORP

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NEUROONE MEDICAL TECHNOLOGIES CORP

 PRESS RELEASE
Free
NMTC NEUROONE MEDICA...

NeuroOne® Receives FDA 510(k) Clearance for OneRF® Trigeminal Nerve Ab...

NeuroOne® Receives FDA 510(k) Clearance for OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain FDA Clearance Further Validates Technology Platform and Offers Alternatives to Pharmaceutical and Invasive Surgical Treatments EDEN PRAIRIE, Minn., Aug. 18, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, has received U.S. Food and Drug Administration (“FDA”) clearance to market its One...

August 18, 2025 1 EN
 PRESS RELEASE
Free
NMTC NEUROONE MEDICA...

NeuroOne® Reports Third Quarter Fiscal Year 2025 Financial Results; Re...

NeuroOne® Reports Third Quarter Fiscal Year 2025 Financial Results; Revenue Increases 105% YoY and Gross Margin Expands to 53.9% Completed Oversubscribed $8.2 Million Capital Raise; Funded Through At Least Fiscal Year 2026 EDEN PRAIRIE, Minn., Aug. 14, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, has reported financial results for the third quarter of fiscal year 2025 ended June 30, 2025. Recent Company...

August 14, 2025 1 EN
 PRESS RELEASE
Free
NMTC NEUROONE MEDICA...

NeuroOne® to Report Third Quarter Fiscal Year 2025 Financial Results o...

NeuroOne® to Report Third Quarter Fiscal Year 2025 Financial Results on Thursday, August 14 at 8:30 a.m. Eastern Time - Update EDEN PRAIRIE, Minn., July 31, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will release financial results for its fiscal third quarter ended June 30, 2025, before market open on August 14, 2025. Management will host an investor conference call and webcast at 8:3...

July 31, 2025 1 EN
 PRESS RELEASE
Free
NMTC NEUROONE MEDICA...

NeuroOne® to Report Third Quarter Fiscal Year 2025 Financial Results o...

NeuroOne® to Report Third Quarter Fiscal Year 2025 Financial Results on Thursday, August 14 at 8:30 a.m. Eastern Time EDEN PRAIRIE, Minn., July 31, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will release financial results for its fiscal third quarter ended June 30, 2025, before market open on August 14, 2025. Management will host an investor conference call and webcast at 8:30 a.m. Ea...

July 31, 2025 1 EN
 PRESS RELEASE
Free
NMTC NEUROONE MEDICA...

NeuroOne® Receives Notice of Allowance for Key Patent from U.S. Patent...

NeuroOne® Receives Notice of Allowance for Key Patent from U.S. Patent & Trademark Office Patent Strengthens Intellectual Property Portfolio Surrounding Neural Probe Technologies EDEN PRAIRIE, Minn., July 23, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, has received a notice of allowance for a key patent from the U.S. Patent and Trademark Office (USPTO) titled, “Methods for Making Probe...

July 23, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch